Dyslipidemia in age-related macular degeneration

38Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Lipid-rich drusen are the sine qua non of age-related macular degeneration (AMD), the leading cause of blindness in older adults in the developed world. Efforts directed at uncovering effective therapeutic strategies have led to the hypothesis that altered lipid metabolism may play a pathogenic role in AMD. This hypothesis is supported by the fact that: (1) drusen, the hallmark histopathologic feature of AMD, are composed of lipids, (2) polymorphisms of genes involved in lipid homeostasis are associated with increased odds of AMD, (3) metabolomics studies show that patients with AMD have alterations in metabolites from lipid pathways, and (4) alterations in serum lipid profiles as a reflection of systemic dyslipidemia are associated with AMD. There is strong evidence that statins, which are well described for treating dyslipidemia and reducing risk associated with cardiovascular disease, may have a role for treating certain cohorts of AMD patients, but this has yet to be conclusively proven. Of interest, the specific changes in serum lipoprotein profiles associated with decreased cardiovascular risk (i.e., high HDL levels) have been shown in some studies to be associated with increased risk of AMD. In this review, we highlight the evidence that supports a role for altered lipid metabolism in AMD and provide our perspective regarding the remaining questions that need to be addressed before lipid-based therapies can emerge for specific cohorts of AMD patients.

References Powered by Scopus

Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes

4590Citations
N/AReaders
Get full text

Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis

3782Citations
N/AReaders
Get full text

Effect of Intensive Compared with Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis: A Randomized Controlled Trial

2193Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Pathophysiology of Age-Related Macular Degeneration: Implications for Treatment

34Citations
N/AReaders
Get full text

Neuroprotection for Age-Related Macular Degeneration

21Citations
N/AReaders
Get full text

The Role of Inflammation in Age-Related Macular Degeneration—Therapeutic Landscapes in Geographic Atrophy

16Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Lin, J. B., Halawa, O. A., Husain, D., Miller, J. W., & Vavvas, D. G. (2022, February 1). Dyslipidemia in age-related macular degeneration. Eye (Basingstoke). Springer Nature. https://doi.org/10.1038/s41433-021-01780-y

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

44%

Professor / Associate Prof. 2

22%

Lecturer / Post doc 2

22%

Researcher 1

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

64%

Biochemistry, Genetics and Molecular Bi... 3

27%

Agricultural and Biological Sciences 1

9%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 7

Save time finding and organizing research with Mendeley

Sign up for free